The combination of pembrolizumab andaxitinib (PAXI) is an approved first-line combination therapy for metastatic renal cell carcinoma (mRCC). A real-world study based out of Italy by Annalisa Guida, MD, and colleagues sought to evaluate the outcomes of this combination and uncover any relevant revelations of characteristic-based adverse events (AEs) for this immunotherapy combination. ...
Renal Cell Carcinoma
Advertisement
Latest News
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
Drs. Samantha Armstrong and Karine Tawagi provide updated commentary on STAMPEDE, SunRISe-4, and SUNNIFORECAST trials.
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
The first part of five segments from the live podcast, roundtable session on radioligands.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Advertisement
Advertisement
Latest News
The first part of five segments from the live podcast, roundtable session on radioligands.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.